mitoxantrone has been researched along with Disease Exacerbation in 107 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In an observational multicenter study, we analyzed retrospectively 30 patients with malignant form of multiple sclerosis (MS) treated with mitoxantrone the year following the first neurological event." | 9.13 | [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year]. ( Debouverie, M; Edan, G; Gout, O; Le Page, E; Malikova, I; Ory, S; Pelletier, J; Roullet, E; Vermersch, P, 2008) |
| "The study's aim was to compare the efficacy and safety of intravenous cyclophosphamide (CTX) and mitoxantrone (MITO) as second-line therapy in a clinical sample of active relapsing-remitting (RR) or secondary-progressive (SP) multiple sclerosis subjects." | 9.13 | Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. ( Amato, MP; Hakiki, B; Portaccio, E; Siracusa, G; Sorbi, S; Zipoli, V, 2008) |
| "Men with HRPC, bone metastases, and bone pain were randomly assigned to receive clodronate 1,500 mg administered intravenously (IV) or placebo every 3 weeks, in combination with mitoxantrone 12 mg/m2 IV every 3 weeks and prednisone 5 mg orally bid." | 9.10 | Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. ( Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW, 2003) |
| "Paclitaxel and mitoxantrone are highly active agents in the treatment of advanced breast cancer (ABC)." | 9.09 | Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study. ( Acito, L; Angiona, S; Bilancia, D; Costanzo, FD; Fioriti, L; Gasperoni, S; Giustini, L; Manzione, L; Sdrobolini, A; Valenti, L, 1999) |
| "This study evaluated mitoxantrone and paclitaxel combination chemotherapy in the treatment of patients with metastatic breast cancer." | 9.09 | Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer. ( Campbell, M; Cantrell, J; Cartmell, A; Ghalie, R; Harvey, J; Modiano, M; Newcomb, T; Rubin, A; Schuster, M; Urba, W, 2001) |
| "The review assessed the efficacy and tolerability of mitoxantrone in patients with neuromyelitis optica spectrum disorder (NMOSD)." | 9.01 | Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. ( Enriquez, CAG; Espiritu, AI; Pasco, PMD, 2019) |
| "Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients." | 8.89 | Mitoxantrone for multiple sclerosis. ( Capra, R; Comi, G; Martinelli Boneschi, F; Rovaris, M; Vacchi, L, 2013) |
| "MEDLINE (1966-present) and the Cochrane Central Register of Controlled Trials (1994-present) were searched for relevant randomized, blinded, controlled clinical trials using the terms mitoxantrone, Novantrone, and multiple sclerosis." | 8.83 | Management of worsening multiple sclerosis with mitoxantrone: a review. ( Fox, EJ, 2006) |
| "Mitoxantrone, an immunosuppressant agent with potent anti-inflammatory activity, has been used to treat patients with multiple sclerosis (MS) who have worsening relapsing-remitting (RRMS) or secondary progressive multiple sclerosis (SPMS) despite prior therapy with interferons or glatiramer acetate." | 8.83 | The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? ( Murray, TJ, 2006) |
| "Mitoxantrone (MITX) and cyclophosphamide (CPM) are potent immunosuppressive agents with efficacy in the treatment of multiple sclerosis (MS)." | 8.82 | The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis. ( Jeffery, DR, 2004) |
| "Our study aimed to describe safety and neurological impact of alemtuzumab as last-line rescue therapy in aggressive multiple sclerosis (MS) patients, previously treated by Mitoxantrone (MITOX)." | 7.81 | Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study. ( Cardiet, I; Deburghgraeve, V; Edan, G; Le Page, E; Leray, E; Lester, MA, 2015) |
| "To evaluate the efficacy of mitoxantrone (MTX) on clinical and neuroradiological parameters of patients who had a relapse of neuromyelitis optica spectrum (NMOS) within the 12 previous months." | 7.79 | Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. ( Cabre, P; Jeannin, S; Marignier, R; Merle, H; Olindo, S; Smadja, D, 2013) |
| "In patients with advanced hepatocellular carcinoma (HCC), combination chemotherapy using 5- fluorouracil, cisplatin, and mitoxantrone (FMP) could achieve a response rate > 20%, but the beneficial effect was compromised by formidable adverse events." | 7.77 | Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. ( Chen, HC; Hsu, CL; Hung, CF; Lin, CC; Pan, KT; Sung, CM; Tseng, JH; Yeh, CT, 2011) |
| "We retrospectively analyzed data from 70 multiple sclerosis (MS) patients treated with mitoxantrone (MX) before Interferon-beta (IFN-beta) because of clinically and MRI very active isolated syndrome (CIS) or relapsing-remitting MS (induction therapy) or due to breakthrough/persistently active disease in spite of IFN-beta (add-on/combination therapy), or for increased disability suggesting a secondary progression (rescue therapy)." | 7.74 | Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis. ( Baldini, SM; Comi, G; Ghezzi, A; Rizzo, A; Zaffaroni, M, 2008) |
| "Mitoxantrone has recently been shown to be effective in ameliorating multiple sclerosis activity and reducing the relapse rate." | 6.73 | Mitoxantrone reduced disability in Iranian patients with multiple sclerosis. ( Etemadifar, M; Hamzehloo, A, 2007) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 6.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| "Mitoxantrone was originally developed as an antineoplastic agent." | 6.45 | [Mitoxantrone for the treatment of patients with multiple sclerosis]. ( Komori, M; Kondo, T; Tanaka, M, 2009) |
| "To investigate the use of docetaxel 75 mg/m(2) intravenously every 3 weeks plus prednisone 5 mg orally twice daily in men with metastatic hormone-refractory prostate cancer (HRPC) progressing after first-line mitoxantrone/prednisone (MP), the primary outcome being progression-free survival with prostatic-specific antigen (PSA) and pain response, toxicity and quality of life (QoL) also assessed." | 5.13 | The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. ( Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E, 2008) |
| "In an observational multicenter study, we analyzed retrospectively 30 patients with malignant form of multiple sclerosis (MS) treated with mitoxantrone the year following the first neurological event." | 5.13 | [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year]. ( Debouverie, M; Edan, G; Gout, O; Le Page, E; Malikova, I; Ory, S; Pelletier, J; Roullet, E; Vermersch, P, 2008) |
| "The study's aim was to compare the efficacy and safety of intravenous cyclophosphamide (CTX) and mitoxantrone (MITO) as second-line therapy in a clinical sample of active relapsing-remitting (RR) or secondary-progressive (SP) multiple sclerosis subjects." | 5.13 | Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. ( Amato, MP; Hakiki, B; Portaccio, E; Siracusa, G; Sorbi, S; Zipoli, V, 2008) |
| "The objective of the current study was to assess the efficacy of combination therapy with fludarabine and mitoxantrone in patients with B-cell chronic lymphocytic leukemia (CLL)." | 5.11 | Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. ( Andreeff, M; Beran, M; Ferrajoli, A; Giles, FJ; Kantarjian, HM; Keating, MJ; Lerner, S; O'Brien, S; Tsimberidou, AM; Wierda, WG, 2004) |
| "To evaluate the effects of mitoxantrone (Mx) in progressive multiple sclerosis (MS) on MRI." | 5.11 | Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. ( Gonsette, R; Hartung, HP; Krapf, H; Morrissey, SP; Zenker, O; Zwingers, T, 2005) |
| "Men with HRPC, bone metastases, and bone pain were randomly assigned to receive clodronate 1,500 mg administered intravenously (IV) or placebo every 3 weeks, in combination with mitoxantrone 12 mg/m2 IV every 3 weeks and prednisone 5 mg orally bid." | 5.10 | Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. ( Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW, 2003) |
| "Paclitaxel and mitoxantrone are highly active agents in the treatment of advanced breast cancer (ABC)." | 5.09 | Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study. ( Acito, L; Angiona, S; Bilancia, D; Costanzo, FD; Fioriti, L; Gasperoni, S; Giustini, L; Manzione, L; Sdrobolini, A; Valenti, L, 1999) |
| "This study evaluated mitoxantrone and paclitaxel combination chemotherapy in the treatment of patients with metastatic breast cancer." | 5.09 | Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer. ( Campbell, M; Cantrell, J; Cartmell, A; Ghalie, R; Harvey, J; Modiano, M; Newcomb, T; Rubin, A; Schuster, M; Urba, W, 2001) |
| "The review assessed the efficacy and tolerability of mitoxantrone in patients with neuromyelitis optica spectrum disorder (NMOSD)." | 5.01 | Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. ( Enriquez, CAG; Espiritu, AI; Pasco, PMD, 2019) |
| "Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients." | 4.89 | Mitoxantrone for multiple sclerosis. ( Capra, R; Comi, G; Martinelli Boneschi, F; Rovaris, M; Vacchi, L, 2013) |
| "MEDLINE (1966-present) and the Cochrane Central Register of Controlled Trials (1994-present) were searched for relevant randomized, blinded, controlled clinical trials using the terms mitoxantrone, Novantrone, and multiple sclerosis." | 4.83 | Management of worsening multiple sclerosis with mitoxantrone: a review. ( Fox, EJ, 2006) |
| "Mitoxantrone, an immunosuppressant agent with potent anti-inflammatory activity, has been used to treat patients with multiple sclerosis (MS) who have worsening relapsing-remitting (RRMS) or secondary progressive multiple sclerosis (SPMS) despite prior therapy with interferons or glatiramer acetate." | 4.83 | The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? ( Murray, TJ, 2006) |
| "Mitoxantrone (MITX) and cyclophosphamide (CPM) are potent immunosuppressive agents with efficacy in the treatment of multiple sclerosis (MS)." | 4.82 | The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis. ( Jeffery, DR, 2004) |
| "Our study aimed to describe safety and neurological impact of alemtuzumab as last-line rescue therapy in aggressive multiple sclerosis (MS) patients, previously treated by Mitoxantrone (MITOX)." | 3.81 | Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study. ( Cardiet, I; Deburghgraeve, V; Edan, G; Le Page, E; Leray, E; Lester, MA, 2015) |
| "To evaluate the efficacy of mitoxantrone (MTX) on clinical and neuroradiological parameters of patients who had a relapse of neuromyelitis optica spectrum (NMOS) within the 12 previous months." | 3.79 | Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. ( Cabre, P; Jeannin, S; Marignier, R; Merle, H; Olindo, S; Smadja, D, 2013) |
| "In patients with advanced hepatocellular carcinoma (HCC), combination chemotherapy using 5- fluorouracil, cisplatin, and mitoxantrone (FMP) could achieve a response rate > 20%, but the beneficial effect was compromised by formidable adverse events." | 3.77 | Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. ( Chen, HC; Hsu, CL; Hung, CF; Lin, CC; Pan, KT; Sung, CM; Tseng, JH; Yeh, CT, 2011) |
| "Mitoxantrone is one of the few FDA-approved drugs available to treat rapidly progressing forms of multiple sclerosis; however, its utilization is compromised by a cardiotoxic potential and the risk of mitoxantrone-induced leukemia." | 3.77 | A novel aza-anthrapyrazole blocks the progression of experimental autoimmune encephalomyelitis after the priming of autoimmunity. ( Gunning, W; Hacker, M; Kiraly, A; Koffman, B; Quinn, A; Rasche, S, 2011) |
| "We retrospectively analyzed data from 70 multiple sclerosis (MS) patients treated with mitoxantrone (MX) before Interferon-beta (IFN-beta) because of clinically and MRI very active isolated syndrome (CIS) or relapsing-remitting MS (induction therapy) or due to breakthrough/persistently active disease in spite of IFN-beta (add-on/combination therapy), or for increased disability suggesting a secondary progression (rescue therapy)." | 3.74 | Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis. ( Baldini, SM; Comi, G; Ghezzi, A; Rizzo, A; Zaffaroni, M, 2008) |
| "We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery." | 3.70 | Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999) |
| "Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers." | 2.75 | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. ( Bodrogi, I; de Bono, JS; Gravis, G; Gupta, S; Hansen, S; Kocak, I; Machiels, JP; Mackenzie, MJ; Oudard, S; Ozguroglu, M; Roessner, M; Sartor, AO; Shen, L, 2010) |
| "Mitoxantrone has recently been shown to be effective in ameliorating multiple sclerosis activity and reducing the relapse rate." | 2.73 | Mitoxantrone reduced disability in Iranian patients with multiple sclerosis. ( Etemadifar, M; Hamzehloo, A, 2007) |
| "In patients with pancreatic cancer, CAI/RT had no significant effect on local recurrence (log-rank P = 0." | 2.73 | Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. ( Hermans, JJ; Hop, WC; Incrocci, L; Jeekel, J; Kazemier, G; Morak, MJ; van Dekken, H; van der Gaast, A; van Eijck, CH, 2008) |
| "Seventy adults with acute promyelocytic leukemia were studied to clarify the significance of the level and kinetics of minimal residual disease (MRD) over their entire treatment course by realtime quantitative polymerase chain reaction." | 2.72 | The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial. ( Cho, SG; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS, 2006) |
| "Mitoxantrone (mitox) has been shown to be effective for secondary progressive (SP) and relapsing-remitting multiple sclerosis (MS)." | 2.71 | [The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients]. ( Brandt, T; Gross, A; Hohlfeld, R; Jahn, K; Strupp, M; Zingler, VC, 2005) |
| "It is hoped that therapeutics in primary progressive multiple sclerosis will continue to expand and effective therapeutic agents will be developed." | 2.71 | Interferon beta-1a in primary progressive multiple sclerosis. ( Leary, SM; Thompson, AJ, 2003) |
| "Patients with hormone refractory prostate cancer who are asymptomatic but had progressive disease had a significantly higher response rate when treated with mitoxantrone and prednisone as demonstrated by the 50% or greater decrease in prostate specific antigen compared to treatment with prednisone alone." | 2.70 | Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. ( Asmar, L; Berry, W; Dakhil, S; Gregurich, M; Modiano, M, 2002) |
| "Men with metastatic prostate cancer (n = 161) were randomized to receive either daily prednisone alone or mitoxantrone (every 3 weeks) plus prednisone." | 2.69 | Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. ( Ernst, DS; Neville, AJ; Osoba, D; Tannock, IF, 1999) |
| " No toxic deaths have occurred." | 2.69 | Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma. ( Budel, L; Doorduijn, JK; Löwenberg, B; Sonneveld, P; Spruit, P; van Der Holt, B; van't Veer, M, 2000) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 2.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| " Thus, a network of multiple-treatments meta-analysis was performed using four clinical outcomes: 'patients free of relapse', 'patients without disease progression', 'patients without MRI progression' and 'patients with adverse events'." | 2.49 | A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. ( Bakalos, G; Doxani, C; Grigoriadis, N; Hadjigeorgiou, GM; Miligkos, M; Mprotsis, T; Papadimitriou, D; Ziakas, P; Zintzaras, E, 2013) |
| "Castration-resistant prostate cancer (CRPC) has historically presented significant challenges to both clinicians and patients in regard to disease progression and consequent management." | 2.49 | Challenges in treating advanced disease. ( Petrylak, DP, 2013) |
| "The burden of prostate cancer is inversely related to the magnitude of HRQOL declines." | 2.48 | Quality of life with advanced metastatic prostate cancer. ( Penson, DF; Resnick, MJ, 2012) |
| "Abiraterone acetate has recently demonstrated a significant improvement in survival when compared to placebo in patients with docetaxel-treated mCRPC." | 2.47 | Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions. ( Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R, 2011) |
| "Multiple sclerosis is a very disabling inflammatory demyelinating disease of the brain of unknown etiology." | 2.45 | Restoring immune suppression in the multiple sclerosis brain. ( Hoek, RM; Huitinga, I; Koning, N; Uitdehaag, BM, 2009) |
| "Mitoxantrone was originally developed as an antineoplastic agent." | 2.45 | [Mitoxantrone for the treatment of patients with multiple sclerosis]. ( Komori, M; Kondo, T; Tanaka, M, 2009) |
| "Relapses are treated with corticosteroids." | 2.43 | [Multiple sclerosis--update]. ( Mattle, HP, 2005) |
| "More than 200 patients with treatment-resistant multiple sclerosis have been transplanted so far, mainly in Europe and the USA." | 2.42 | Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experience. ( Fassas, A; Kimiskidis, VK, 2004) |
| " The affected tumors remained dormant long after dosing stopped, resulting in a prolonged progression-free survival and sustained immune surveillance of the host bearing desmoplastic melanoma." | 1.48 | Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma. ( Chen, F; Hou, L; Huang, L; Liu, Q; Shen, L; Wang, D; Zhang, X, 2018) |
| "For patients with acute myeloid leukemia from antecedent myelodysplastic syndrome particularly after azanucleoside treatment failure, outcome is poor." | 1.40 | Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. ( Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E, 2014) |
| "Multiple sclerosis is the most common chronic disabling disease of the central nervous system in young adults." | 1.37 | Multiple sclerosis- diagnosis, management and prognosis. ( Macdonell, R; Tsang, BK, 2011) |
| "Mitoxantrone (MTX) is an immunosuppressive drug approved for multiple sclerosis (MS) treatment." | 1.36 | Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. ( Comi, G; Esposito, F; Martinelli Boneschi, F; Martinelli, V; Moiola, L; Radaelli, M; Rocca, MA; Rodegher, M; Sormani, MP, 2010) |
| "Nine anaphylactoid reactions, two severe, were reported." | 1.35 | Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. ( Jensen, PE; Koch-Henriksen, N; Oturai, AB; Petersen, T; Sellebjerg, F; Sorensen, PS, 2009) |
| "The median time to disease progression and median survival were 1." | 1.31 | Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. ( Blume, KG; Chao, NJ; Feiner, RH; Hu, WW; Johnston, LJ; Long, GD; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, K; Wong, RM, 2000) |
| "Seventeen patients had small lymphocytic lymphoma (SLL), 29 had follicular lymphoma (FL), 10 of them with histologic transformation." | 1.31 | Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. ( Caracciolo, D; Corradini, P; Cuttica, A; Gavarotti, P; Ladetto, M; Novero, D; Pileri, A; Rossi, G; Tarella, C; Zallio, F, 2000) |
| "We report a patient with acute myelomonocytic leukemia (AMMoL) who showed two independent point mutations of the N-ras gene at codons 12 and 13." | 1.29 | Double mutations of the N-ras gene in a patient with acute myelomonocytic leukemia. ( Hirakawa, K; Horiike, S; Kaneko, H; Kashima, K; Misawa, S; Nakai, H; Nakao, M; Taniwaki, M; Ueda, Y, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.93) | 18.7374 |
| 1990's | 16 (14.95) | 18.2507 |
| 2000's | 63 (58.88) | 29.6817 |
| 2010's | 27 (25.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fernández, Ó | 1 |
| Khamidulla, A | 1 |
| Kabdrakhmanova, G | 1 |
| Utepkaliyeva, A | 1 |
| Darin, D | 1 |
| Urasheva, Z | 1 |
| Liu, Q | 1 |
| Chen, F | 1 |
| Hou, L | 1 |
| Shen, L | 2 |
| Zhang, X | 1 |
| Wang, D | 1 |
| Huang, L | 1 |
| Enriquez, CAG | 1 |
| Espiritu, AI | 1 |
| Pasco, PMD | 1 |
| Martinelli Boneschi, F | 2 |
| Vacchi, L | 1 |
| Rovaris, M | 1 |
| Capra, R | 1 |
| Comi, G | 3 |
| Kumar, S | 1 |
| Sharma, P | 1 |
| Kumar, D | 1 |
| Chakraborty, G | 1 |
| Gorain, M | 1 |
| Kundu, GC | 1 |
| Hadjigeorgiou, GM | 1 |
| Doxani, C | 1 |
| Miligkos, M | 1 |
| Ziakas, P | 1 |
| Bakalos, G | 1 |
| Papadimitriou, D | 1 |
| Mprotsis, T | 1 |
| Grigoriadis, N | 1 |
| Zintzaras, E | 1 |
| Jaglal, MV | 1 |
| Duong, VH | 1 |
| Bello, CM | 1 |
| Al Ali, NH | 1 |
| Padron, E | 1 |
| Fernandez, HF | 1 |
| List, AF | 1 |
| Lancet, JE | 1 |
| Komrokji, RS | 1 |
| Petrylak, DP | 1 |
| Broadley, SA | 1 |
| Barnett, MH | 1 |
| Boggild, M | 1 |
| Brew, BJ | 1 |
| Butzkueven, H | 1 |
| Heard, R | 1 |
| Hodgkinson, S | 1 |
| Kermode, AG | 1 |
| Lechner-Scott, J | 1 |
| Macdonell, RA | 1 |
| Marriott, M | 1 |
| Mason, DF | 1 |
| Parratt, J | 1 |
| Reddel, SW | 1 |
| Shaw, CP | 1 |
| Slee, M | 1 |
| Spies, J | 1 |
| Taylor, BV | 1 |
| Carroll, WM | 1 |
| Kilpatrick, TJ | 1 |
| King, J | 1 |
| McCombe, PA | 1 |
| Pollard, JD | 1 |
| Willoughby, E | 1 |
| Sedal, L | 1 |
| Wilson, IB | 1 |
| McDonald, EA | 1 |
| Le Page, E | 2 |
| Deburghgraeve, V | 1 |
| Lester, MA | 1 |
| Cardiet, I | 1 |
| Leray, E | 1 |
| Edan, G | 3 |
| Hussain, M | 1 |
| Rathkopf, D | 1 |
| Liu, G | 1 |
| Armstrong, A | 1 |
| Kelly, WK | 1 |
| Ferrari, A | 1 |
| Hainsworth, J | 1 |
| Joshi, A | 1 |
| Hozak, RR | 1 |
| Yang, L | 1 |
| Schwartz, JD | 1 |
| Higano, CS | 1 |
| Saad, F | 1 |
| Ruether, D | 1 |
| Ernst, S | 1 |
| North, S | 1 |
| Cheng, T | 1 |
| Perrotte, P | 1 |
| Karakiewicz, P | 1 |
| Winquist, E | 1 |
| Blasier, MG | 1 |
| Fu, K | 1 |
| Weisenburger, DD | 1 |
| Choi, WW | 1 |
| Perry, KD | 1 |
| Smith, LM | 1 |
| Shi, X | 1 |
| Hans, CP | 1 |
| Greiner, TC | 1 |
| Bierman, PJ | 1 |
| Bociek, RG | 1 |
| Armitage, JO | 1 |
| Chan, WC | 1 |
| Vose, JM | 1 |
| Zaffaroni, M | 1 |
| Rizzo, A | 1 |
| Baldini, SM | 1 |
| Ghezzi, A | 1 |
| Ory, S | 1 |
| Debouverie, M | 2 |
| Pelletier, J | 1 |
| Malikova, I | 1 |
| Gout, O | 1 |
| Roullet, E | 1 |
| Vermersch, P | 2 |
| Kale, N | 1 |
| Icen, M | 1 |
| Agaoglu, J | 1 |
| Yazici, I | 1 |
| Tanik, O | 1 |
| Morak, MJ | 1 |
| van der Gaast, A | 1 |
| Incrocci, L | 1 |
| van Dekken, H | 1 |
| Hermans, JJ | 1 |
| Jeekel, J | 1 |
| Hop, WC | 1 |
| Kazemier, G | 1 |
| van Eijck, CH | 1 |
| Webb, UH | 1 |
| Oturai, AB | 1 |
| Koch-Henriksen, N | 1 |
| Petersen, T | 1 |
| Jensen, PE | 1 |
| Sellebjerg, F | 1 |
| Sorensen, PS | 1 |
| Olbert, PJ | 1 |
| Weil, C | 1 |
| Hegele, A | 1 |
| Hofmann, R | 1 |
| Schrader, AJ | 1 |
| Makhani, N | 1 |
| Gorman, MP | 1 |
| Branson, HM | 1 |
| Stazzone, L | 1 |
| Banwell, BL | 1 |
| Chitnis, T | 1 |
| Komori, M | 1 |
| Kondo, T | 1 |
| Tanaka, M | 1 |
| Koning, N | 1 |
| Uitdehaag, BM | 2 |
| Huitinga, I | 1 |
| Hoek, RM | 1 |
| Weinshenker, BG | 1 |
| Sazonov, DV | 1 |
| Malkova, NA | 1 |
| Bulatova, EV | 1 |
| Riabukhina, OV | 1 |
| van der Voort, LF | 1 |
| Gilli, F | 1 |
| Bertolotto, A | 1 |
| Knol, DL | 1 |
| Polman, CH | 1 |
| Killestein, J | 1 |
| Zagoskina, TP | 1 |
| Tkachenko, SB | 1 |
| Golubeva, ME | 1 |
| Kudriavtseva, AV | 1 |
| Isaeva, NV | 1 |
| Malykh, OV | 1 |
| Wundes, A | 1 |
| Kraft, GH | 1 |
| Bowen, JD | 1 |
| Gooley, TA | 1 |
| Nash, RA | 1 |
| Launay, M | 1 |
| Lebrun, C | 1 |
| Giordana, E | 1 |
| Chanalet, S | 1 |
| Thomas, P | 1 |
| Esposito, F | 1 |
| Radaelli, M | 1 |
| Martinelli, V | 1 |
| Sormani, MP | 1 |
| Moiola, L | 1 |
| Rocca, MA | 1 |
| Rodegher, M | 1 |
| de Bono, JS | 1 |
| Oudard, S | 2 |
| Ozguroglu, M | 1 |
| Hansen, S | 1 |
| Machiels, JP | 1 |
| Kocak, I | 1 |
| Gravis, G | 1 |
| Bodrogi, I | 1 |
| Mackenzie, MJ | 1 |
| Roessner, M | 1 |
| Gupta, S | 1 |
| Sartor, AO | 1 |
| Ansari, J | 1 |
| Hussain, SA | 1 |
| Alhasso, A | 1 |
| Mahmood, R | 1 |
| Ansari, A | 1 |
| Glaholm, J | 1 |
| Yeh, CT | 1 |
| Chen, HC | 1 |
| Sung, CM | 1 |
| Hsu, CL | 1 |
| Lin, CC | 1 |
| Pan, KT | 1 |
| Tseng, JH | 1 |
| Hung, CF | 1 |
| Berger, JR | 1 |
| Kiraly, A | 1 |
| Koffman, B | 1 |
| Hacker, M | 1 |
| Gunning, W | 1 |
| Rasche, S | 1 |
| Quinn, A | 1 |
| Tsang, BK | 1 |
| Macdonell, R | 1 |
| Resnick, MJ | 1 |
| Penson, DF | 1 |
| Eisenberger, MA | 1 |
| Antonarakis, ES | 1 |
| Cabre, P | 1 |
| Olindo, S | 1 |
| Marignier, R | 1 |
| Jeannin, S | 1 |
| Merle, H | 1 |
| Smadja, D | 1 |
| Mauro, FR | 1 |
| Foa, R | 1 |
| Meloni, G | 1 |
| Gentile, M | 1 |
| Giammartini, E | 1 |
| Giannarelli, D | 1 |
| De Propris, MS | 1 |
| Rapanotti, MC | 1 |
| de Fabritiis, P | 1 |
| Mandelli, F | 1 |
| Pender, MP | 1 |
| Wolfe, NP | 1 |
| Berry, W | 1 |
| Dakhil, S | 1 |
| Modiano, M | 2 |
| Gregurich, M | 1 |
| Asmar, L | 1 |
| O'Connor, P | 1 |
| Leary, SM | 1 |
| Thompson, AJ | 1 |
| Ernst, DS | 2 |
| Tannock, IF | 2 |
| Winquist, EW | 1 |
| Venner, PM | 1 |
| Reyno, L | 1 |
| Moore, MJ | 1 |
| Chi, K | 1 |
| Ding, K | 1 |
| Elliott, C | 1 |
| Parulekar, W | 1 |
| Freedman, MS | 2 |
| Atkins, HL | 1 |
| Tsimberidou, AM | 1 |
| Keating, MJ | 1 |
| Giles, FJ | 2 |
| Wierda, WG | 1 |
| Ferrajoli, A | 1 |
| Lerner, S | 1 |
| Beran, M | 1 |
| Andreeff, M | 1 |
| Kantarjian, HM | 1 |
| O'Brien, S | 1 |
| Jeffery, DR | 2 |
| Fassas, A | 1 |
| Kimiskidis, VK | 1 |
| Vandenberghe, N | 1 |
| Morrissey, SP | 2 |
| Anxionnat, R | 1 |
| Pittion-Vouyovitch, S | 1 |
| Vespignani, H | 1 |
| Sheen, WC | 1 |
| Chen, JS | 1 |
| Wang, HM | 1 |
| Yang, TS | 1 |
| Liaw, CC | 1 |
| Lin, YC | 1 |
| Weide, R | 1 |
| Pandorf, A | 1 |
| Heymanns, J | 1 |
| Köppler, H | 1 |
| Cohen, BA | 1 |
| Khan, O | 1 |
| Bashir, K | 1 |
| Rizvi, SA | 2 |
| Fox, EJ | 2 |
| Agius, M | 1 |
| Bashir, R | 1 |
| Collins, TE | 1 |
| Herndon, R | 1 |
| Kinkel, P | 1 |
| Mikol, DD | 1 |
| Picone, MA | 1 |
| Rivera, V | 1 |
| Tornatore, C | 1 |
| Zwibel, H | 1 |
| Agius, MA | 1 |
| Schmid, P | 1 |
| Schippinger, W | 1 |
| Nitsch, T | 1 |
| Huebner, G | 1 |
| Heilmann, V | 1 |
| Schultze, W | 1 |
| Hausmaninger, H | 1 |
| Wischnewsky, M | 1 |
| Possinger, K | 1 |
| Blokhin, DIu | 1 |
| Banu, E | 1 |
| Beuzeboc, P | 1 |
| Voog, E | 1 |
| Dourthe, LM | 1 |
| Hardy-Bessard, AC | 1 |
| Linassier, C | 1 |
| Scotté, F | 1 |
| Banu, A | 1 |
| Coscas, Y | 1 |
| Guinet, F | 1 |
| Poupon, MF | 1 |
| Andrieu, JM | 1 |
| Zingler, VC | 1 |
| Strupp, M | 1 |
| Jahn, K | 1 |
| Gross, A | 1 |
| Hohlfeld, R | 1 |
| Brandt, T | 1 |
| Moore, CN | 1 |
| George, DJ | 1 |
| Ostberg, A | 1 |
| Pittas, F | 1 |
| Taylor, B | 1 |
| Benesova, Y | 1 |
| Stourac, P | 1 |
| Beranek, M | 1 |
| Kadanka, Z | 1 |
| Mattle, HP | 1 |
| Krapf, H | 1 |
| Zenker, O | 1 |
| Zwingers, T | 1 |
| Gonsette, R | 1 |
| Hartung, HP | 1 |
| Enschede, SH | 1 |
| Porter, C | 1 |
| Venugopal, P | 1 |
| Gregory, SA | 1 |
| Kaufmann, M | 1 |
| Schmid, H | 1 |
| Raeth, U | 1 |
| Fox, RJ | 1 |
| Bethoux, F | 1 |
| Goldman, MD | 1 |
| Cohen, JA | 1 |
| Michels, J | 1 |
| Montemurro, T | 1 |
| Murray, N | 2 |
| Kollmannsberger, C | 1 |
| Nguyen Chi, K | 1 |
| Murray, TJ | 1 |
| Burton, C | 1 |
| Linch, D | 1 |
| Hoskin, P | 1 |
| Milligan, D | 1 |
| Dyer, MJ | 1 |
| Hancock, B | 1 |
| Mouncey, P | 1 |
| Smith, P | 1 |
| Qian, W | 1 |
| MacLennan, K | 1 |
| Jack, A | 1 |
| Webb, A | 1 |
| Cunningham, D | 1 |
| Lee, S | 1 |
| Kim, YJ | 1 |
| Eom, KS | 1 |
| Min, CK | 1 |
| Kim, HJ | 1 |
| Cho, SG | 1 |
| Lee, JW | 1 |
| Min, WS | 1 |
| Kim, CC | 1 |
| Burgess, EF | 1 |
| Roth, BJ | 1 |
| Nadeau, SE | 1 |
| Hamzehloo, A | 1 |
| Etemadifar, M | 1 |
| Zipoli, V | 1 |
| Portaccio, E | 1 |
| Hakiki, B | 1 |
| Siracusa, G | 1 |
| Sorbi, S | 1 |
| Amato, MP | 1 |
| Boiardi, A | 2 |
| Silvani, A | 2 |
| Eoli, M | 2 |
| Lamperti, E | 1 |
| Salmaggi, A | 2 |
| Gaviani, P | 1 |
| Fiumani, A | 1 |
| Botturi, A | 1 |
| Falcone, C | 1 |
| Solari, A | 1 |
| Filippini, G | 1 |
| Di Meco, F | 1 |
| Broggi, G | 2 |
| Zéphir, H | 1 |
| de Sèze, J | 1 |
| Dujardin, K | 1 |
| Dubois, G | 1 |
| Cabaret, M | 1 |
| Bouillaguet, S | 1 |
| Ferriby, D | 1 |
| Stojkovic, T | 1 |
| Horiike, S | 1 |
| Misawa, S | 1 |
| Kaneko, H | 1 |
| Nakai, H | 1 |
| Ueda, Y | 1 |
| Nakao, M | 1 |
| Hirakawa, K | 1 |
| Taniwaki, M | 1 |
| Kashima, K | 1 |
| Martinelli, G | 1 |
| Testoni, N | 2 |
| Zuffa, E | 1 |
| Visani, G | 2 |
| Zinzani, PL | 1 |
| Zaccaria, A | 1 |
| Farabegoli, P | 1 |
| Arpinati, M | 1 |
| Amabile, M | 1 |
| Tura, S | 2 |
| Look, RM | 1 |
| Lim, SW | 1 |
| Waxman, AD | 1 |
| Gupta, PK | 1 |
| Fuerst, MM | 1 |
| Kusuanco, DA | 1 |
| Lawrence, GN | 1 |
| Davidge-Pitts, M | 1 |
| Dansey, R | 1 |
| Bezwoda, WR | 1 |
| Stewart, DJ | 1 |
| Dahrouge, S | 1 |
| Ellis, P | 1 |
| Smith, I | 1 |
| Ashley, S | 1 |
| Walsh, G | 1 |
| Ebbs, S | 1 |
| Baum, M | 1 |
| Sacks, N | 1 |
| McKinna, J | 1 |
| Makris, A | 1 |
| Powles, TJ | 1 |
| Dowsett, M | 1 |
| Osborne, CK | 1 |
| Trott, PA | 1 |
| Fernando, IN | 1 |
| Ashley, SE | 1 |
| Ormerod, MG | 1 |
| Titley, JC | 1 |
| Gregory, RK | 1 |
| Allred, DC | 1 |
| Kurbacher, CM | 1 |
| Bruckner, HW | 1 |
| Cree, IA | 1 |
| Kurbacher, JA | 1 |
| Wilhelm, L | 1 |
| Pöch, G | 1 |
| Indefrei, D | 1 |
| Mallmann, P | 1 |
| Andreotti, PE | 1 |
| Lemoli, RM | 1 |
| Leopardi, G | 1 |
| Motta, MR | 1 |
| Rizzi, S | 1 |
| Curti, A | 1 |
| Husain, A | 1 |
| Sabbatini, P | 1 |
| Spriggs, D | 1 |
| Fennelly, D | 1 |
| Aghajanian, C | 1 |
| Barakat, R | 1 |
| Curtin, J | 1 |
| Venkatraman, E | 1 |
| Hoskins, W | 1 |
| Markman, M | 1 |
| Costanzo, FD | 1 |
| Sdrobolini, A | 1 |
| Manzione, L | 1 |
| Bilancia, D | 1 |
| Acito, L | 1 |
| Gasperoni, S | 1 |
| Valenti, L | 1 |
| Fioriti, L | 1 |
| Angiona, S | 1 |
| Giustini, L | 1 |
| Berger, E | 1 |
| Rumbach, L | 1 |
| Wattel, E | 1 |
| Solary, E | 1 |
| Hecquet, B | 1 |
| Caillot, D | 1 |
| Ifrah, N | 1 |
| Brion, A | 1 |
| Milpied, N | 1 |
| Janvier, M | 1 |
| Guerci, A | 1 |
| Rochant, H | 1 |
| Cordonnier, C | 1 |
| Dreyfus, F | 1 |
| Veil, A | 1 |
| Hoang-Ngoc, L | 1 |
| Stoppa, AM | 1 |
| Gratecos, N | 1 |
| Sadoun, A | 1 |
| Tilly, H | 1 |
| Brice, P | 1 |
| Lioure, B | 1 |
| Desablens, B | 1 |
| Pignon, B | 1 |
| Abgrall, JP | 1 |
| Leporrier, M | 1 |
| Fenaux, P | 1 |
| Osoba, D | 1 |
| Neville, AJ | 1 |
| Kakolyris, S | 1 |
| Kourousis, C | 1 |
| Koukourakis, M | 1 |
| Androulakis, N | 1 |
| Vamvakas, L | 1 |
| Agelaki, S | 1 |
| Hatzidaki, D | 1 |
| Samonis, G | 1 |
| Tsiftsis, D | 1 |
| Georgoulias, V | 1 |
| Hu, WW | 2 |
| Negrin, RS | 2 |
| Stockerl-Goldstein, K | 1 |
| Johnston, LJ | 2 |
| Shizuru, JA | 1 |
| Wong, RM | 1 |
| Chao, NJ | 1 |
| Long, GD | 1 |
| Feiner, RH | 1 |
| Blume, KG | 2 |
| Tarella, C | 1 |
| Caracciolo, D | 1 |
| Corradini, P | 1 |
| Zallio, F | 1 |
| Ladetto, M | 1 |
| Cuttica, A | 1 |
| Rossi, G | 1 |
| Novero, D | 1 |
| Gavarotti, P | 1 |
| Pileri, A | 1 |
| Pozzi, A | 1 |
| Doorduijn, JK | 1 |
| Spruit, P | 1 |
| van Der Holt, B | 1 |
| van't Veer, M | 1 |
| Budel, L | 1 |
| Löwenberg, B | 1 |
| Sonneveld, P | 1 |
| Stockerl-Goldstein, KE | 1 |
| Hoppe, RT | 1 |
| Horning, SJ | 1 |
| Harvey, J | 1 |
| Cantrell, J | 1 |
| Campbell, M | 1 |
| Cartmell, A | 1 |
| Urba, W | 1 |
| Schuster, M | 1 |
| Rubin, A | 1 |
| Newcomb, T | 1 |
| Ghalie, R | 1 |
| Seiter, K | 1 |
| Feldman, EJ | 1 |
| Sreekantaiah, C | 1 |
| Pozzuoli, M | 1 |
| Weisberger, J | 1 |
| Liu, D | 1 |
| Papageorgio, C | 1 |
| Weiss, M | 1 |
| Kancherla, R | 1 |
| Ahmed, T | 1 |
| Chi, KN | 1 |
| Gleave, ME | 1 |
| Klasa, R | 1 |
| Bryce, C | 1 |
| Lopes de Menezes, DE | 1 |
| D'Aloisio, S | 1 |
| Tolcher, AW | 1 |
| MacLean, HJ | 1 |
| Myers, LW | 1 |
| Suminoe, A | 1 |
| Matsuzaki, A | 1 |
| Hattori, H | 1 |
| Ishii, S | 1 |
| Hara, T | 1 |
| Bagert, B | 1 |
| Camplair, P | 1 |
| Bourdette, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Cellular Stromal Vascular Fraction (cSVF) for Select Multiple Sclerosis, Autoimmune, Inflammatory, and Neurologic Conditions: Clinical Interventional Study of Adverse Events and Clinical Outcomes Using Autologous Stem-Stromal Cells.[NCT02939859] | Phase 1 | 0 participants (Actual) | Interventional | 2018-12-15 | Withdrawn (stopped due to Withdrawn [COVID restrictions prevent patient enrollment or treatment. Clinical Trial facility is being closed due to viral limitations and loss of staff to perform]) | ||
| A Phase 2, Multicenter, Randomized Study of IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer (AIPC) Following Disease Progression on Docetaxel-Based Chemotherapy[NCT00683475] | Phase 2 | 138 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer[NCT01859221] | 39 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| Prospective Pilot Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer[NCT04225910] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2020-01-01 | Not yet recruiting | ||
| Predictive fActors for toleraNce to Taxane Based CHemotherapy In Older adultS Affected by mEtastatic Prostate Cancer, a Prospective Observational Study (ANCHISES)[NCT05471427] | 118 participants (Actual) | Observational | 2020-01-01 | Completed | |||
| A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone[NCT04015622] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
| A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone[NCT01848067] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2013-08-14 | Completed | ||
| A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated [NCT00417079] | Phase 3 | 755 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT01379339] | Phase 1 | 40 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Randomized Phase II Study of OGX-427 (a Second-Generation Antisense Oligonucleotide to Heat Shock Protein-27) in Patients With Castration Resistant Prostate Cancer Who Have Not Previously Received Chemotherapy for Metastatic Disease[NCT01120470] | Phase 2 | 74 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.[NCT04962919] | 590 participants (Anticipated) | Observational | 2020-01-14 | Recruiting | |||
| An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)[NCT06056791] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis[NCT03461419] | 100 participants (Anticipated) | Interventional | 2019-08-01 | Suspended (stopped due to Withdrawn [COVID restrictions prevent patient enrollment or treatment. Clinical Trial facility is being closed due to viral limitations and loss of staff to perform]) | |||
| Comparison of Expanded Disability Status Scale, Gad-enhanced Brain Lesions, Annualized Relapse Rate, and Side Effects Between Active Secondary Progressive Multiple Sclerosis Patients on Rituximab and Glatiramer Acetate[NCT03315923] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2017-12-01 | Completed | ||
| MOSAIC-P: Mindfulness Online for Symptom Alleviation and Improvement in Cancer of the Prostate[NCT03853902] | 30 participants (Actual) | Interventional | 2016-01-26 | Completed | |||
| Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain[NCT00003232] | Phase 3 | 227 participants (Actual) | Interventional | 1997-11-24 | Completed | ||
| Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis[NCT03113162] | Phase 1 | 15 participants (Anticipated) | Interventional | 2015-05-29 | Recruiting | ||
| A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)[NCT03737370] | Phase 1 | 25 participants (Anticipated) | Interventional | 2018-01-30 | Recruiting | ||
| Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)[NCT02258217] | 30 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer[NCT00004001] | Phase 3 | 770 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Defined as the median time from randomization to the earliest of:~Tumor progression by Response Evaluation Criteria in Solid Tumors (RECIST);~Evidence of progression by bone scan, performed after completion of the first 3 cycles, demonstrating the appearance of >=2 new lesions;~New skeletal events (New pathologic bone fracture in the region of metastatic disease; New bone lesion requiring radiation or surgery; Spinal cord or nerve root compression)~Symptomatic progression (for participants without measurable disease);~Other clinical events attributable to prostate cancer that require major interventions; or~Death from any cause~Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy." (NCT00683475)
Timeframe: Randomization to composite progressive disease, up to 23.4 months
| Intervention | months (Median) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 4.1 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 6.7 |
"Data presented are the percentage of participants without disease progression at 12 months.~Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy." (NCT00683475)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 12.4 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 20.0 |
"Data presented are the percentage of participants without disease progression at 6 months.~Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy." (NCT00683475)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 37.2 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 59.2 |
"Data presented are the percentage of participants without disease progression at 9 months.~Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy." (NCT00683475)
Timeframe: 9 months
| Intervention | percentage of participants (Number) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 20.7 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 35.9 |
"Objective response is Complete Response (CR) + Partial Response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is a disappearance of all target and non-target lesions; PR is at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions.~Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with measurable disease, multiplied by 100." (NCT00683475)
Timeframe: Baseline to date of progressive disease or death up to 36.3 months
| Intervention | percentage of participants (Number) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 15.2 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 31.6 |
Overall survival is defined as the time from randomization to the date of death due to any cause. Participants who were alive at the time of study completion were censored at the time the participant was last known to be alive. (NCT00683475)
Timeframe: First dose to death due to any cause up to 36.3 months
| Intervention | months (Median) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 10.8 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 13.0 |
PSA response rate is defined as the percentage of participants with a decrease in PSA >= 50 percent from baseline. (NCT00683475)
Timeframe: Baseline up to data cut-off date (up to 36.3 months)
| Intervention | percentage of participants (Number) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 18.5 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 21.4 |
"Time between date of randomization and earliest date of radiographic progression defined as either:~Tumor progression by RECIST;~Evidence of progression by bone scan;~New skeletal events (New pathologic bone fracture in the region of metastatic disease; New bone lesion requiring radiation or surgery; Spinal cord or nerve root compression).~Participants who were ongoing with no radiographic evidence of disease progression, who discontinued treatment for reasons other than progression,or died before progression were censored at date of last tumor or bone radiographic assessment. Participants who started a new anticancer treatment before progression were censored at date of last tumor or bone radiographic assessment before start of new anti-cancer therapy." (NCT00683475)
Timeframe: Randomization to date of radiographic progression, up to 36.3 months
| Intervention | months (Median) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 7.5 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 10.2 |
Data presented are the number of participants who experienced A12 or 1121B (ramucirumab) related treatment-emergent adverse events (TEAE), treatment related serious adverse events (SAE), or any Grade 3 or higher TEAE; any TEAE leading to discontinuation of A12 or 1121B (ramucirumab) treatment, and any TEAE leading to dose modification of A12 or 1121B (ramucirumab). A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Event section. (NCT00683475)
Timeframe: Randomization to 36.3 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| A12/1121B Related TEAE | A12/1121B Related Serious TEAE | A12/1121B Related Grade >= 3 TEAE | TEAE Leading to Dose Modification of A12/1121B | TEAE Leading to Discontinuation of A12/1121B | |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 63 | 16 | 31 | 35 | 25 |
| IMC-A12 + Mitoxantrone + Prednisone | 64 | 22 | 35 | 35 | 18 |
Compared between the two patient subsets using the nonparametric Mann-Whitney test. A comparison of CTC counts between baseline and at progression for those who have progressed will be carried out using either a paired t test or the nonparameteric Wilcoxon matched pairs test. (NCT01848067)
Timeframe: Baseline up to 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 3 |
Summarized with descriptive statistics. (NCT01848067)
Timeframe: Up to 21 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 2 |
"Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause.~In the absence of confirmation of death, the survival time was censored at the last date patient was known to be alive or at the cut-off date, whichever had come first." (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 12.7 |
| Cabazitaxel + Prednisone | 15.1 |
"Tumor Overall Response Rate (ORR) (only in patients with measurable disease):~Objective responses (Complete Response and Partial Response) for measurable disease as assessed by investigators according to RECIST criteria.~Complete Response (CR) is defined as: Disappearance of all target lesions. Partial Response (PR) is defined as: At least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference baseline sum LD.~Confirmation of objective responses will be performed by repeat tumor imaging (CT scans, MRI, bone scans) after the first documentation of response." (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 4.4 |
| Cabazitaxel + Prednisone | 14.4 |
Pain Response was defined as a two-point or greater reduction from baseline median Present Pain Intensity (PPI) score without an increased Analgesic Score (AS) or a decrease of ≥50% in the AS without an increase in the PPI score, maintained for at least 3 weeks. (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 7.7 |
| Cabazitaxel + Prednisone | 9.2 |
PSA response was defined as a ≥ 50% reduction in serum PSA, determined only for patients with a serum PSA ≥ 20ng/mL at baseline, confirmed by a repeat PSA ≥ 3 weeks later. (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 17.8 |
| Cabazitaxel + Prednisone | 39.2 |
"Pain Progression is defined as an increase of ≥1 point in the median Personal Pain Intensity (PPI) from its nadir noted on 2 consecutive 3-week-apart visits or ≥25 % increase in the mean analgesic score compared with the baseline score & noted on 2 consecutive 3-week-apart visits or requirement for local palliative radiotherapy.~Evaluation of the PPI & analgesic scores are based on the short-form McGill Pain Questionnaire which consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0=none (best) 1=mild 2=moderate 3=severe (worst) (TOTAL: 0=best 45=worst)" (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | NA |
| Cabazitaxel + Prednisone | 11.1 |
Progression free survival was defined as a composite endpoint evaluated from the date of randomization to the date of tumor progression, PSA progression, pain progression, or death due to any cause, whichever occurred first (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 1.4 |
| Cabazitaxel + Prednisone | 2.8 |
"In PSA non-responders, progression will be defined as a 25% increase over nadir and increase in the absolute value PSA level by at least 5 ng/ml and confirmed by a second value at least 4 weeks later.~In PSA responders and in patients not evaluable for PSA response at baseline, progression will be defined as a ≥50% increase over nadir, provided that the increase is a minimum of 5 ng/ml and confirmed by a second value at least 1 week later." (NCT00417079)
Timeframe: at screening, day 1 of every treatment cycle, up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 3.1 |
| Cabazitaxel + Prednisone | 6.4 |
Time to tumor progression is defined as the number of months from randomization until evidence of progressive disease (RECIST) (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 5.4 |
| Cabazitaxel + Prednisone | 8.8 |
"Patients completed the ARMS survey after treatment for the new relapse.The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~The TCS score was calculated only for the time point after treatment of relapse. It was a sum of questions 4 (symptom improvement), 5 (ADL), and 6 (return to previous state of health (RSH)) were evaluated. Scores range from 0 to 30 units, with higher scores representing greater improvement/better functioning." (NCT02258217)
Timeframe: Follow-up visit
| Intervention | score on a scale (Mean) |
|---|---|
| Single Arm | 14.3 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, history of patients from the survey after treatment for the new relapse will be collected.~The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~ADL scores were calculated from Part 1 (new relapse), question 3 and Part 2 (after treatment of relapse), question 5 both specifically refer to ADL;~Scale: ADL (Activities of Daily Living) Minimum value: 0 Maximum value: 9 Higher scores indicated better functioning/ improvement." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| ADL (new relapse) | ADL (after treatment of relapse) | |
| Single Arm | 3.1 | 4.9 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, patients completed the survey after treatment for the new relapse.~The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~PCS was computed based on the sum of the ADL and RSH questions. The PCS was computed separately for Part 1 (new relapse) and Part 2 (after relapse treatment) and summarized descriptively; Higher scores indicating better functioning/greater improvement. The PCS scores were on a scale of 0 to 20 units." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| PCS (New relapse) | PCS (after treatment of relapse) | |
| Single Arm | 7.7 | 9.2 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, patients completed the survey after treatment for the new relapse. The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~Part 1 (new relapse) & Part 2 (after treatment of new relapse), question 6 were used to calculate RSH;~Scale: RSH (Return to previous health) Minimum value: -1 Maximum value: 10 Higher scores indicating a more complete return to previous state of health." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| RSH (new relapse) | RSH (after treatment of new relapse) | |
| Single Arm | 4.6 | 4.4 |
"This scaling score is obtained by performing a neurologic exam with specific attention to eight different neurologic functional systems: visual, pyramidal, cerebellar, bowel and bladder, cerebral, brainstem, sensory and other (10). The score is rated from zero (normal neurologic examination) to ten (death due to MS). This is the standard neurologic disability scale used in clinical trials for the evaluation of disability in patients with MS.~These scores were compared between pre and post phase using paired t-tests." (NCT02258217)
Timeframe: baseline and at follow-up
| Intervention | score on a scale (Median) | |
|---|---|---|
| EDSS score (new relapse) | EDSS score (after treatment of new relapse) | |
| Single Arm | 3.5 | 3.0 |
"Patients who reported a history of poor corticosteroid tolerability will be placed on Acthar and GASE scale will be given to assess tolerability to Acthar.~We listed the number of times a symptom was reported and was attributable to the ACTHAR treatment" (NCT02258217)
Timeframe: 1 week
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Headache | Dry Mouth | Dizziness | Tachycardia, palpitation or arrhythmia | Breathing problems | Abdominal pain | Nausea | Diarrhea | Reduced Appetite | Increased appetite | Difficulties with urination | Skin rash or itching | Tendency to develop bruises | Sweating | Hot flashes | Fatigue, loss of energy | Insomnia, sleeping problems | Nightmares or abnormal dreams | Back pain | Agitation | Irritability | Depressed Mood | Anxiety, fearfulness | Further symptoms | |
| Single Arm | 3 | 1 | 2 | 1 | 1 | 4 | 4 | 4 | 1 | 4 | 2 | 1 | 1 | 1 | 1 | 2 | 8 | 2 | 1 | 6 | 6 | 3 | 1 | 8 |
"The MSIS-29 is a self-reported questionnaire in which MS patients answer a series of 29 questions designed to capture the impact of multiple sclerosis on their life over the past 2 weeks (11). Twenty of the 29 questions assess the physical impact of MS and 9 questions assess the psychological impact of MS.~The psychological impact of MS was compared between pre and post phase using paired t-tests.~The psychological impact of MS was compared between pre and post phase using paired t-tests.~The score was on a scale of 9 to 45 points for MSIS psychological score.~Higher score indicate worse outcome." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MSIS psychological(new relapse) | MSIS psychological(after treatment of new relapse) | |
| Single Arm | 29.4 | 26.3 |
"The MSIS-29 is a self-reported questionnaire in which MS patients answer a series of 29 questions designed to capture the impact of multiple sclerosis on their life over the past 2 weeks (11). Twenty of the 29 questions assess the physical impact of MS.~The physical impact of MS was compared between pre and post phase using paired t-tests. Each question is answered with points ranging from 1 to 5. Higher score indicates worse outcome. The total MSIS physical score ranges from 20 to 100 points with lower points indicating better impact." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Median) | |
|---|---|---|
| MSIS physical (new relapse) | MSIS physical (after treatment of new relapse) | |
| Single Arm | 58.5 | 56 |
"The Self-Administered Gerocognitive Exam (SAGE) is designed to detect early signs of cognitive, memory or thinking impairments. It evaluates your thinking abilities and helps physicians to know how well your brain is working.~It consists of 12 questions which are scored at different scales. The final SAGE score is calculated as a sum of these 12 questions and it ranges from 0 to 22.~Higher score indicates better outcome." (NCT02258217)
Timeframe: baseline and follow-up
| Intervention | score on a scale (Median) | |
|---|---|---|
| SAGE (new relapse) | SAGE (after treatment of new relapse) | |
| Single Arm | 21 | 21 |
34 reviews available for mitoxantrone and Disease Exacerbation
| Article | Year |
|---|---|
Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
Topics: Alemtuzumab; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; | 2017 |
[MODERN APPROACHES TO THE TREATMENT OF MULTIPLE SCLEROSIS (REVIEW AND CLINICAL CASE)].
Topics: Adolescent; Alemtuzumab; Disease Progression; Drug Administration Schedule; Female; Humans; Immunolo | 2018 |
Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.
Topics: Cardiomyopathies; Disease Progression; Epidemiologic Studies; Humans; Immunosuppressive Agents; Infe | 2019 |
Mitoxantrone for multiple sclerosis.
Topics: Disease Progression; Humans; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis; Multiple Sc | 2013 |
A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.
Topics: Data Interpretation, Statistical; Disease Progression; Glatiramer Acetate; Interferon beta-1a; Inter | 2013 |
Challenges in treating advanced disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III | 2013 |
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
Topics: Adult; Antibodies, Monoclonal, Humanized; Australia; Clinical Trials as Topic; Disease Management; D | 2014 |
Current management of relapsing-remitting multiple sclerosis.
Topics: Administration, Intravenous; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; C | 2014 |
Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials a | 2008 |
[Mitoxantrone for the treatment of patients with multiple sclerosis].
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dise | 2009 |
Restoring immune suppression in the multiple sclerosis brain.
Topics: Animals; Antibodies; Antigens, CD; Brain; Disease Progression; Glatiramer Acetate; Glucocorticoids; | 2009 |
[Rescue treatments for multiple sclerosis].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2009 |
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cl | 2011 |
Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies.
Topics: Activities of Daily Living; Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
Quality of life with advanced metastatic prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Deno | 2012 |
Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects.
Topics: Adjuvants, Immunologic; Autoimmune Diseases; Azathioprine; B-Lymphocytes; Cyclophosphamide; Disease | 2002 |
Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
Topics: Clinical Trials as Topic; Disease Progression; Glatiramer Acetate; Humans; Immunoglobulins, Intraven | 2002 |
The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis.
Topics: Cyclophosphamide; Disease Progression; Humans; Immunosuppressive Agents; Immunotherapy; Inflammation | 2004 |
Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experience.
Topics: Clinical Trials as Topic; Disease Progression; Hematopoietic Stem Cell Transplantation; Hematopoieti | 2004 |
Identifying and treating patients with suboptimal responses.
Topics: Clinical Trials as Topic; Consensus Development Conferences as Topic; Disability Evaluation; Disease | 2004 |
Current approved options for treating patients with multiple sclerosis.
Topics: Clinical Trials as Topic; Disease Progression; Drug Approval; Glatiramer Acetate; Humans; Immunologi | 2004 |
[The multidrug tumor cell resistance phenotype caused by the impaired cell death program].
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Disease Progres | 2004 |
Update in the management of patients with hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Calcitriol; Calcium Channel Agon | 2005 |
[Multiple sclerosis--update].
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Adult; Diagnosis, Differential; Disease Progression | 2005 |
Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease Progressio | 2006 |
The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?
Topics: Disease Progression; Heart; Heart Diseases; Humans; Immunosuppressive Agents; Leukemia; Mitoxantrone | 2006 |
Changing perspectives of the role of chemotherapy in advanced prostate cancer.
Topics: Androgens; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Docetaxel; Estramus | 2006 |
Management of worsening multiple sclerosis with mitoxantrone: a review.
Topics: Anti-Inflammatory Agents; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Immunosup | 2006 |
[New therapeutic strategies in multiple sclerosis].
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents; Brain; Clinical Trials as Topic; Disease Progressi | 1999 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chrom | 2001 |
Immunologic therapy for relapsing-remitting multiple sclerosis.
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Autoimmune Diseases; Azat | 2001 |
Immunologic therapy for secondary and primary progressive multiple sclerosis.
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antilymphocyte Ser | 2001 |
Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis.
Topics: Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Resi | 2001 |
Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.
Topics: Adjuvants, Immunologic; Brain; Cognition Disorders; Depressive Disorder; Diagnosis, Differential; Di | 2002 |
36 trials available for mitoxantrone and Disease Exacerbation
| Article | Year |
|---|---|
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2015 |
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; | 2008 |
[Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].
Topics: Adult; Disease Progression; Female; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance | 2008 |
Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2008 |
[Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Dise | 2009 |
[Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphocytic leukemia].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease Progressio | 2002 |
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 2002 |
Interferon beta-1a in primary progressive multiple sclerosis.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Agents; Disability Evaluation; Disease Pro | 2003 |
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clodronic Acid; Disease Progre | 2003 |
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up | 2004 |
Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease P | 2005 |
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2005 |
[The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients].
Topics: Adult; Aged; Analgesics; Disease Progression; Drug Combinations; Female; Humans; Male; Methylprednis | 2005 |
Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
Topics: Adult; Antineoplastic Agents; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle A | 2005 |
Mitoxantrone therapy in rapidly worsening multiple sclerosis.
Topics: Disease Progression; Female; Humans; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis, Chronic Pr | 2005 |
Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Topics: Adult; Antineoplastic Agents; Central Nervous System; Disease Progression; Dose-Response Relationshi | 2005 |
Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Pr | 2004 |
First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Proto | 2006 |
A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyc | 2006 |
The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; | 2006 |
Mitoxantrone reduced disability in Iranian patients with multiple sclerosis.
Topics: Adolescent; Adult; Analgesics; Disability Evaluation; Disease Progression; Female; Follow-Up Studies | 2007 |
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Blood Cell Count; Cyclophosphamide; Disease Progres | 2008 |
[Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study].
Topics: Adult; Analgesics; Anti-Inflammatory Agents; Cognition Disorders; Depression; Disease Progression; F | 2008 |
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 1997 |
Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone | 1997 |
Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disea | 1999 |
Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 1999 |
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protoco | 1999 |
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1999 |
First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplas | 1999 |
Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Ma | 2000 |
Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2001 |
A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2001 |
37 other studies available for mitoxantrone and Disease Exacerbation
| Article | Year |
|---|---|
Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Progressio | 2018 |
Functional characterization of stromal osteopontin in melanoma progression and metastasis.
Topics: Animals; Carcinogenesis; Cell Communication; Cell Proliferation; Cell Separation; Disease Progressio | 2013 |
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Co | 2014 |
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cohort Studies; Disabi | 2015 |
Pharmacologic management of multiple sclerosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Disease Management; Disease Progression; | 2008 |
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis.
Topics: Adolescent; Adult; Antineoplastic Agents; Disability Evaluation; Disease Progression; Drug Administr | 2008 |
Clustering of organ-specific autoimmunity: a case presentation of multiple sclerosis and connective tissue disorders.
Topics: Activities of Daily Living; Autoimmune Diseases; Autoimmunity; Brain; Cluster Analysis; Connective T | 2008 |
Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.
Topics: Adolescent; Adult; Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Denmark; | 2009 |
Cyclophosphamide therapy in pediatric multiple sclerosis.
Topics: Adolescent; Age Factors; Age of Onset; Child; Cyclophosphamide; Disease Progression; Drug Administra | 2009 |
[Combined therapy of aggressive remitted multiple sclerosis with mitoxantrone in combination with copaxone].
Topics: Adjuvants, Immunologic; Adult; Analgesics; Disease Progression; Drug Therapy, Combination; Female; F | 2009 |
Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
Topics: Adult; Antibodies, Neutralizing; Antineoplastic Agents; Central Nervous System; Disability Evaluatio | 2010 |
Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.
Topics: Adolescent; Adult; Antineoplastic Agents; Blood Cell Count; Clinical Protocols; Disability Evaluatio | 2010 |
[Clinical, radiographic, prognostic and therapeutic aspects of demelinating disease with tumefactive demyelinating lesions].
Topics: Adolescent; Case-Control Studies; Comorbidity; Disease Progression; Drug Therapy, Combination; Evoke | 2011 |
Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.
Topics: Adolescent; Adult; Aged; Disability Evaluation; Disease Progression; Female; Humans; Immunosuppressi | 2010 |
Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Protocols; Dise | 2011 |
A novel aza-anthrapyrazole blocks the progression of experimental autoimmune encephalomyelitis after the priming of autoimmunity.
Topics: Animals; Autoimmunity; Cytokines; Disease Models, Animal; Disease Progression; Encephalomyelitis, Au | 2011 |
Multiple sclerosis- diagnosis, management and prognosis.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Australia; Diagnosis, Differential; Disease Pr | 2011 |
Multiple sclerosis- diagnosis, management and prognosis.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Australia; Diagnosis, Differential; Disease Pr | 2011 |
Multiple sclerosis- diagnosis, management and prognosis.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Australia; Diagnosis, Differential; Disease Pr | 2011 |
Multiple sclerosis- diagnosis, management and prognosis.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Australia; Diagnosis, Differential; Disease Pr | 2011 |
Multiple sclerosis- diagnosis, management and prognosis.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Australia; Diagnosis, Differential; Disease Pr | 2011 |
Multiple sclerosis- diagnosis, management and prognosis.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Australia; Diagnosis, Differential; Disease Pr | 2011 |
Multiple sclerosis- diagnosis, management and prognosis.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Australia; Diagnosis, Differential; Disease Pr | 2011 |
Multiple sclerosis- diagnosis, management and prognosis.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Australia; Diagnosis, Differential; Disease Pr | 2011 |
Multiple sclerosis- diagnosis, management and prognosis.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Australia; Diagnosis, Differential; Disease Pr | 2011 |
The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cytotoxins; Disease Progression; Docetaxel; | 2012 |
Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Cohort Studies; Disability Evaluation; Disea | 2013 |
Suppressing immunity in advancing MS: too much too late, or too late for much?
Topics: Animals; Bone Marrow Transplantation; Disease Progression; Hematopoietic Stem Cell Transplantation; | 2004 |
Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
Topics: Adult; Disability Evaluation; Disease Progression; Female; Humans; Magnetic Resonance Imaging; Male; | 2004 |
A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administrati | 2004 |
Mitoxantrone and prednimustine combination chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administ | 1989 |
Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Topics: Adult; Brain; Contrast Media; Disease Progression; Gadolinium; Humans; Mitoxantrone; Multiple Sclero | 2006 |
Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Topics: Adult; Aged; Aging; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combi | 2008 |
Double mutations of the N-ras gene in a patient with acute myelomonocytic leukemia.
Topics: Aclarubicin; Alleles; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosom | 1995 |
FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Bone Marrow Transplantati | 1996 |
Technetium-99m sestamibi scanning in multiple myeloma stem cell transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Dise | 1996 |
Salvage treatment after failure or relapse following initial chemotherapy for follicular non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cycl | 1997 |
Mitoxantrone in the treatment of metastatic transitional cell carcinoma of the prostate. A case report.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1997 |
Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Ne | 1998 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Mod | 1999 |
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
Topics: Adjuvants, Pharmaceutic; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; B | 2000 |
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cycloph | 2000 |
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy | 1999 |
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bo | 2000 |